1. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study;Leichman;J Clin Oncol,1995
2. Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA). Assessment report: Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products, 2020. https://www.ema.europa.eu/en/documents/referral/fluorouracil-fluorouracil-related-substances-article-31-referral-assessment-report_en.pdf. Accessed July 14, 2022.
3. INCa and HAS. Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine), 2018. https://www.has-sante.fr/jcms/c_2891090/en/screening-for-dihydropyrimidine-dehydrogenase-deficiency-to-decrease-the-risk-of-severe-toxicities-related-to-fluoropyrimidines-5-fluorouracil-or-capecitabine-inahta-brief. Accessed August 11, 2022.
4. M.C. Etienne-Grimaldi, J.C. Boyer, C. Beroud, L. Mbatchi, A. van Kuilenburg, C. Bobin-Dubigeon, F. Thomas, E. Chatelut, J.L. Merlin, F. Pinguet, C. Ferrand, J. Meijer, A. Evrard, L. Llorca, G. Romieu, P. Follana, T. Bachelot, L. Chaigneau, X. Pivot, V. Dieras, R. Largillier, M. Mousseau, A. Goncalves, H. Roché, J. Bonneterre, V. Servent, N. Dohollou, Y. Château, E. Chamorey, J.P. Desvignes, D. Salgado, J.M. Ferrero, G. Milano, New advances in DPYD genotype and risk of severe toxicity under capecitabine, PLoS One 12(5) (2017) e0175998.
5. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study;de With;Clinical Pharmacology & Therapeutics,2022